1
|
Lazzeroni D, Rimoldi O and Camici PG: From
left ventricular hypertrophy to dysfunction and failure. Circ J.
80:555–564. 2016.PubMed/NCBI View Article : Google Scholar
|
2
|
Shimizu I and Minamino T: Physiological
and pathological cardiac hypertrophy. J Mol Cell Cardiol.
97:245–262. 2016.PubMed/NCBI View Article : Google Scholar
|
3
|
Frey N and Olson EN: Cardiac hypertrophy:
The good, the bad, and the ugly. Annu Rev Physiol. 65:45–79.
2003.PubMed/NCBI View Article : Google Scholar
|
4
|
Luo M, Chen PP, Yang L, Wang P, Lu YL, Shi
FG, Gao Y, Xu SF, Gong QH, Xu RX and Deng J: Sodium ferulate
inhibits myocardial hypertrophy induced by abdominal coarctation in
rats: Involvement of cardiac PKC and MAPK signaling pathways.
Biomed Pharmacother. 112(108735)2019.PubMed/NCBI View Article : Google Scholar
|
5
|
Li X, Lan Y, Wang Y, Nie M, Lu Y and Zhao
E: Telmisartan suppresses cardiac hypertrophy by inhibiting
cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway. Mol
Med Rep. 15:2574–2582. 2017.PubMed/NCBI View Article : Google Scholar
|
6
|
Rai V, Sharma P, Agrawal S and Agrawal DK:
Relevance of mouse models of cardiac fibrosis and hypertrophy in
cardiac research. Mol Cell Biochem. 424:123–145. 2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Tsutsui H, Kinugawa S and Matsushima S:
Oxidative stress and heart failure. Am J Physiol Heart Circ
Physiol. 301:H2181–H2190. 2011.PubMed/NCBI View Article : Google Scholar
|
8
|
Zhang C, Wang F, Zhang Y, Kang Y, Wang H,
Si M, Su L, Xin X, Xue F, Hao F, et al: Celecoxib prevents pressure
overload-induced cardiac hypertrophy and dysfunction by inhibiting
inflammation, apoptosis and oxidative stress. J Cell Mol Med.
20:116–127. 2016.PubMed/NCBI View Article : Google Scholar
|
9
|
Uddin S, Bhat AA, Krishnankutty R, Mir F,
Kulinski M and Mohammad RM: Involvement of F-BOX proteins in
progression and development of human malignancies. Semin Cancer
Biol. 36:18–32. 2016.PubMed/NCBI View Article : Google Scholar
|
10
|
Wang B, Xu M, Li M, Wu F, Hu S, Chen X,
Zhao L, Huang Z, Lan F, Liu D and Wang Y: miR-25 promotes
cardiomyocyte proliferation by targeting FBXW7. Mol Ther Nucleic
Acids. 19:1299–1308. 2020.PubMed/NCBI View Article : Google Scholar
|
11
|
Wang L, Qin D, Shi H, Zhang Y, Li H and
Han Q: MiR-195-5p promotes cardiomyocyte hypertrophy by targeting
MFN2 and FBXW7. Biomed Res Int. 2019(1580982)2019.PubMed/NCBI View Article : Google Scholar
|
12
|
Thompson BJ, Buonamici S, Sulis ML,
Palomero T, Vilimas T, Basso G, Ferrando A and Aifantis I: The
SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell
leukemia. J Exp Med. 204:1825–1835. 2007.PubMed/NCBI View Article : Google Scholar
|
13
|
Welcker M and Clurman BE: FBW7 ubiquitin
ligase: A tumour suppressor at the crossroads of cell division,
growth and differentiation. Nat Rev Cancer. 8:83–93.
2008.PubMed/NCBI View
Article : Google Scholar
|
14
|
Tan Y, Sangfelt O and Spruck C: The
Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett.
271:1–12. 2008.PubMed/NCBI View Article : Google Scholar
|
15
|
Fu Q, Lu Z, Fu X, Ma S and Lu X: MicroRNA
27b promotes cardiac fibrosis by targeting the FBW7/Snail pathway.
Aging (Albany NY). 11:11865–11879. 2019.PubMed/NCBI View Article : Google Scholar
|
16
|
Tetzlaff MT, Yu W, Li M, Zhang P, Finegold
M, Mahon K, Harper JW, Schwartz RJ and Elledge SJ: Defective
cardiovascular development and elevated cyclin E and Notch proteins
in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA.
101:3338–3345. 2004.PubMed/NCBI View Article : Google Scholar
|
17
|
Kim YC and Guan KL: mTOR: A pharmacologic
target for autophagy regulation. J Clin Invest. 125:25–32.
2015.PubMed/NCBI View
Article : Google Scholar
|
18
|
Gao C, Fan F, Chen J, Long Y, Tang S,
Jiang C and Xu Y: FBW7 regulates the autophagy signal in mesangial
cells induced by high glucose. Biomed Res Int.
2019(6061594)2019.PubMed/NCBI View Article : Google Scholar
|
19
|
Alebiosu CO, Odusan O and Jaiyesimi A:
Morbidity in relation to stage of diabetic nephropathy in type-2
diabetic patients. J Natl Med Assoc. 95:1042–1047. 2003.PubMed/NCBI
|
20
|
Diep QN, El Mabrouk M, Yue P and Schiffrin
EL: Effect of AT(1) receptor blockade on cardiac apoptosis in
angiotensin II-induced hypertension. Am J Physiol Heart Circ
Physiol. 282:H1635–H1641. 2002.PubMed/NCBI View Article : Google Scholar
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
22
|
Berenji K, Drazner MH, Rothermel BA and
Hill JA: Does load-induced ventricular hypertrophy progress to
systolic heart failure? Am J Physiol Heart Circ Physiol.
289:H8–H16. 2005.PubMed/NCBI View Article : Google Scholar
|
23
|
Kavey RE: Left ventricular hypertrophy in
hypertensive children and adolescents: predictors and prevalence.
Curr Hypertens Rep. 15:453–457. 2013.PubMed/NCBI View Article : Google Scholar
|
24
|
Shimizu K, Nihira NT, Inuzuka H and Wei W:
Physiological functions of FBW7 in cancer and metabolism. Cell
Signal. 46:15–22. 2018.PubMed/NCBI View Article : Google Scholar
|
25
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011.PubMed/NCBI View
Article : Google Scholar
|
26
|
Yamaguchi O: Autophagy in the heart. Circ
J. 83:697–704. 2019.PubMed/NCBI View Article : Google Scholar
|
27
|
Xie CM and Sun Y: The MTORC1-mediated
autophagy is regulated by the FBXW7-SHOC2-RPTOR axis. Autophagy.
15:1470–1472. 2019.PubMed/NCBI View Article : Google Scholar
|
28
|
Oldfield CJ, Duhamel TA and Dhalla NS:
Mechanisms for the transition from physiological to pathological
cardiac hypertrophy. Can J Physiol Pharmacol. 98:74–84.
2020.PubMed/NCBI View Article : Google Scholar
|
29
|
Kvansakul M, Caria S and Hinds MG: The
Bcl-2 family in host-virus interactions. Viruses.
9(290)2017.PubMed/NCBI View
Article : Google Scholar
|
30
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for
ubiquitylation and destruction. Nature. 471:104–109.
2011.PubMed/NCBI View Article : Google Scholar
|
31
|
Samak M, Fatullayev J, Sabashnikov A,
Zeriouh M, Schmack B, Farag M, Popov AF, Dohmen PM, Choi YH,
Wahlers T and Weymann A: Cardiac hypertrophy: An introduction to
molecular and cellular basis. Med Sci Monit Basic Res. 22:75–79.
2016.PubMed/NCBI View Article : Google Scholar
|
32
|
Yang L, Li Y, Wang X, Mu X, Qin D, Huang
W, Alshahrani S, Nieman M, Peng J, Essandoh K, et al:
Overexpression of miR-223 tips the balance of pro- and
anti-hypertrophic signaling cascades toward physiologic cardiac
hypertrophy. J Biol Chem. 291:15700–15713. 2016.PubMed/NCBI View Article : Google Scholar
|
33
|
Chen X, Li HD, Bu FT, Li XF, Chen Y, Zhu
S, Wang JN, Chen SY, Sun YY, Pan XY, et al: Circular RNA circFBXW4
suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7
axis. Theranostics. 10:4851–4870. 2020.PubMed/NCBI View Article : Google Scholar
|
34
|
Sawyer DB, Siwik DA, Xiao L, Pimentel DR,
Singh K and Colucci WS: Role of oxidative stress in myocardial
hypertrophy and failure. J Mol Cell Cardiol. 34:379–388.
2002.PubMed/NCBI View Article : Google Scholar
|
35
|
Sugden PH and Clerk A: Oxidative stress
and growth-regulating intracellular signaling pathways in cardiac
myocytes. Antioxid Redox Signal. 8:2111–2124. 2006.PubMed/NCBI View Article : Google Scholar
|
36
|
Guan XH, Hong X, Zhao N, Liu XH, Xiao YF,
Chen TT, Deng LB, Wang XL, Wang JB, Ji GJ, et al: CD38 promotes
angiotensin II-induced cardiac hypertrophy. J Cell Mol Med.
21:1492–1502. 2017.PubMed/NCBI View Article : Google Scholar
|
37
|
Grandel U, Fink L, Blum A, Heep M, Buerke
M, Kraemer HJ, Mayer K, Bohle RM, Seeger W, Grimminger F and
Sibelius U: Endotoxin-induced myocardial tumor necrosis
factor-alpha synthesis depresses contractility of isolated rat
hearts: Evidence for a role of sphingosine and
cyclooxygenase-2-derived thromboxane production. Circulation.
102:2758–2764. 2000.PubMed/NCBI View Article : Google Scholar
|
38
|
Yokoyama T, Nakano M, Bednarczyk JL,
McIntyre BW, Entman M and Mann DL: Tumor necrosis factor-alpha
provokes a hypertrophic growth response in adult cardiac myocytes.
Circulation. 95:1247–1252. 1997.PubMed/NCBI View Article : Google Scholar
|
39
|
Bradham WS, Bozkurt B, Gunasinghe H, Mann
D and Spinale FG: Tumor necrosis factor-alpha and myocardial
remodeling in progression of heart failure: a current perspective.
Cardiovasc Res. 53:822–830. 2002.PubMed/NCBI View Article : Google Scholar
|
40
|
Bai Y, Sun X, Chu Q, Li A, Qin Y, Li Y,
Yue E, Wang H, Li G, Zahra SM, et al: Caspase-1 regulate
AngII-induced cardiomyocyte hypertrophy via upregulation of IL-1β.
Biosci Rep. 38(BSR20171438)2018.PubMed/NCBI View Article : Google Scholar
|
41
|
Matsumoto A, Tateishi Y, Onoyama I, Okita
Y, Nakayama K and Nakayama KI: Fbxw7β resides in the endoplasmic
reticulum membrane and protects cells from oxidative stress. Cancer
Sci. 102:749–755. 2011.PubMed/NCBI View Article : Google Scholar
|
42
|
Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan
F, Liao H and Chi K: FBXW7 promotes pathological cardiac
hypertrophy by targeting EZH2-SIX1 signaling. Exp Cell Res.
393(112059)2020.PubMed/NCBI View Article : Google Scholar
|
43
|
Shen Y, Chen X, Chi C, Wang H, Xue J, Su
D, Wang H, Li M, Liu B and Dong Q: Smooth muscle cell-specific
knockout of FBW7 exacerbates intracranial atherosclerotic stenosis.
Neurobiol Dis. 132(104584)2019.PubMed/NCBI View Article : Google Scholar
|